Obstet Gynecol Sci Search

CLOSE


Obstet Gynecol Sci > Volume 66(5); 2023 > Article
Iavazzo, Fotiou, Kokkali, and Vrachnis: Nomograms to predict overall survival for patients with endometrial carcinosarcoma
Dear editor, we read a very interesting article entitled “a personalized nomogram for predicting 3-year overall survival of patients with uterine carcinosarcoma in a tertiary care hospital in Southern Thailand” by Nanthamongkolkul et al. [1].
The authors presented their retrospective study analyzing a cohort of patients with uterine carcinosarcoma and how body mass index (BMI), International Federation of Gynecology and Obstetrics (FIGO) stage, and adjuvant chemotherapy can affect the 3-year overall survival. The authors combined three parameters to form their nomogram; one presenting the individual’s performance status (BMI), one presenting the tumor’s aggressiveness (FIGO stage), and one presenting the medical approach (adjuvant chemotherapy). They aimed to form a nomogram in which these parameters could predict the 3-year overall survival of patients with uterine carcinosarcoma.
Recently, Chen et al. [2] in their multivariate analysis showed that age, race, year of diagnosis, FIGO stage, and treatment type can also be associated with survival and formed a similar nomogram with a good predictive capacity. Another study formed a nomogram predicting the overall survival of patients with ovarian carcinosarcoma including the following parameters: age, grade, tumor site, surgery, and chemotherapy [3]. We would like to ask the authors whether the addition of patients’ age and surgery might improve the prognostic performance of their nomogram.
Moreover, Gao et al. [4] revealed in their study that log odds of metastatic lymph nodes (LODDS) has a better predicting accuracy compared to the number of positive lymph nodes and lymph node ratio. They suggest that a nomogram based on LODDS can offer an accurate predictive model of the overall survival of patients with uterine carcinosarcoma [4]. A possible modification of the nomogram by the team from Thailand might include such parameters (age, surgery, and LODDS). Would such additions improve their predictive model?
Once again, we would like to thank the authors for their study.

Notes

Conflict of interest

Nothing to declare.

Ethical approval

As a comment with no patients’ data, no ethical approval is necessary.

Patient consent

As no patients’ data are used, there is no necessity for patient consent.

Funding information

Nothing to declare.

References

1. Nanthamongkolkul K, Taweerat P, Jiamset I. A personalized nomogram for predicting 3-year overall survival of patients with uterine carcinosarcoma in a tertiary care hospital in Southern Thailand. Obstet Gynecol Sci 2023;66:198-207.
crossref pmid pmc pdf
2. Chen M, He X, Yang Q, Zhang J, Peng J, Wang D, et al. Epidemiology and prediction model of patients with carcinosarcoma in the United States. Front Public Health 2022;10:1038211.
crossref pmid pmc
3. Liu Y, Lin X, Xue L, Wen Y, Wang S, Wang X. Establishment and validation of a novel nomogram for survival prediction of ovarian carcinosarcoma. Transl Cancer Res 2022;11:52-62.
crossref pmid pmc
4. Gao L, Lyu J, Luo X, Zhang D, Jiang G, Zhang X, et al. Nomogram to predict overall survival based on the log odds of positive lymph nodes for patients with endometrial carcinosarcoma after surgery. BMC Cancer 2021;21:1149.
crossref pmid pmc pdf


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
POLICY
FOR CONTRIBUTORS
Editorial Office
4th Floor, 36 Gangnam-daero 132-gil, Gangnam-gu, Seoul 06044, Korea.
Tel: +82-2-2266-7238    Fax: +82-2-3445-2440    E-mail: journal@ogscience.org                

Copyright © 2024 by Korean Society of Obstetrics and Gynecology.

Developed in M2PI

Close layer
prev next